Phase 3b Study of STN1011402 ophthalmic cream in Patients With Allergic Conjunctivitis

JRCT ID: jRCT2051220050

Registered date:16/06/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Allergic Conjunctivitis
• Date of first enrollment: 25/06/2022
• Target sample size: 50
• Study type: Interventional
• Intervention(s): 0.5% STN1011402 ophthalmic cream (approximately 30mg/time, once a day) and 0.1% Epinastine hydrochloride ophthalmic solution (1 drop/time, twice a day) will be applied for 2 weeks at a time.

Outcome(s)

• Primary Outcome: Usability and burden of use (Questionnaire)

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Provided signed, written informed consent.
Has a positive result from a Type I allergy test.

Exclude criteria

Eye disease other than allergic conjunctivitis is present and requires treatment.
Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.

Related Information

• Primary Sponsor: Kayoko Sakamoto